You are here: Industry Insights > IMU-838

News List

IMU-838 shows some clinical benefit in moderate COVID-19 patients europeanpharmaceuticalreview
February 22, 2021
The oral treatment slightly shortened time to clinical improvement and recovery in a Phase II trial, with greatest benefits in high-risk and elderly COVID-19 patients.
EIB to support COVID-19 therapy with €24.5 million investment europeanpharmaceuticalreview
October 22, 2020
The European Investment Bank (EIB) will provide Immunic with up to €24.5 million to support the ongoing development of IMU-838, a potential COVID-19 therapy.
Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19 prnewswire
September 30, 2020
Immunic, Inc. announced the results of a pre-planned interim safety analysis and a recruitment update from the ongoing phase 2 CALVID-1 trial of its selective oral DHODH inhibitor, IMU-838, in patients with moderate coronavirus disease 2019 (COVID-19).
Immunic Begins IMU-838, Oseltamivir Trial for COVID-19 americanpharmaceuticalreview
July 31, 2020
Immunic announced enrollment of the first patients in an investigator-sponsored phase 2 clinical trial of the company's selective oral DHODH inhibitor, IMU-838, for the treatment of patients with coronavirus disease 2019 (COVID-19).
Immunic Announces FDA Allowance of IMU-838 Trial americanpharmaceuticalreview
June 18, 2020
Immunic announced receipt of regulatory allowance from the U.S. Food and Drug Administration (FDA) to initiate its phase 2, CALVID-1 clinical trial of IMU-838, the company's selective oral DHODH inhibitor, in coronavirus disease 2019 (COVID-19) at centers
Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19 prnewswire
June 16, 2020
Immunic, Inc., a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases.
Immunic Reports IMU-838 Demonstrates Preclinical Activity Against SARS-CoV-2 americanpharmaceuticalreview
April 24, 2020
Immunic reported that its lead asset, IMU-838, a selective oral DHODH inhibitor, has successfully demonstrated preclinical activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).